Nubeqa (darolutamide)

pCPA File Number: 23390

Negotiation Status:

Active Negotiation

Indication(s):

For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

Sponsor/Manufacturer:

Bayer Inc.

CDA-AMC Project Number:

PC0404-000

pCPA Engagement Letter Issued:

2025-10-22

Negotiation Process Concluded:

Not Applicable